A Multicenter, Open-Label Single-Arm Study of YONDELIS (trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Excluding Leiomyosarcoma and Liposarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment
The purpose of this study is to allow eligible, previously-treated patients with soft tissue cancer who cannot take part in other clinical trials to have access to this experimental drug.
*Patient must be 15 years or older
*Have unresectable advanced or metastatic histologically proven soft tissue sarcoma.
*Patient must have had prior chemotherapy.
*Last treatment was 3 weeks or more ago.
*Subject's medical history will be reviewed in detail for study eligibility.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Approximately 4 months on average
Clinical Trials Information Line: Phone 503-494-1080 or email@example.com
Janssen Pharmaceutical Research & Development, L.L.C.